SEC Form 4 · accession 0001333277-19-000026
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sujal Shah
Officer — Chief Executive Officer · Director
Period of report
Jan 29, 2019
Accepted (ET)
Jan 31, 2019 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $8.43 | Jan 29, 2019 | A | 328,492 | A | — | Jan 28, 2029 | Common Stock | 328,492 | 328,492 | D |
Explanation of responses
- F1The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter.